

5<sup>th</sup> May 2023

|   |   |
|---|---|
| BSE Limited<br>Phiroze Jeejeebhoy Towers<br>Dalal Street,<br>Mumbai - 400 001<br><b>Scrip Code: BSE – AJANTPHARM 532331</b> | National Stock Exchange of India<br>Exchange Plaza, 5 <sup>th</sup> Floor, Plot No.<br>C/1, G block, Bandra Kurla Complex,<br>Bandra (East), Mumbai - 400 051<br><b>Scrip Code: NSE AJANTPHARM EQ</b> |
|---|---|

**Subject: - Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI  
(Listing Obligations and Disclosure Requirements), 2015**

Dear Sir / Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions in the prescribed format for the half year ended 31<sup>st</sup> March 2023.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

**Gaurang Shah**

*VP – Legal & Company Secretary*

Encl.: a/a









| Related party transactions                                    |   |     |  |     |   |                                   |  |   |  | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. |   |                 |   |                               |      |        |   |       |                   |
|---|---|-----|--|-----|---|-----------------------------------|--|---|--|--|---|-----------------|---|-------------------------------|------|--------|---|-------|-------------------|
| Sr No.  | Details of the party (listed entity/subsidiary) entering into the transaction |     | Details of the counterparty  |     |   | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of transaction during the reporting period   | In case monies are due to either party as a result of the transaction |                 | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments |                               |      |        |   | Notes |                   |
|   | Name  | PAN | Name   | PAN | Relationship of the counterparty with the listed entity or its subsidiary |                                   |  |   |  |  | Opening balance   | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.)   | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ inter-corporate deposit/ investment) |       | Interest Rate (%) |
| 60  | Ajanta Pharma Limited   |     | Gabs Investments Pvt Ltd   |     | Promoter  | Dividend paid                     |  | N.A.  | 8.81                                   | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 61  | Ajanta Pharma Limited   |     | Arvind Agrawal   |     | Chief Financial Officer & KMP   | Dividend paid                     |  | N.A.  | 0.03                                   | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 62  | Ajanta Pharma Limited   |     | Gaurang Shah   |     | Company Secretary & KMP   | Dividend paid                     |  | N.A.  | 0                                      | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 63  | Ajanta Pharma Limited   |     | Chandrakant Khetan   |     | Independent Director  | Dividend paid                     |  | N.A.  | 0                                      | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 64  | Ajanta Pharma Limited   |     | Yogesh M Agrawal, trustee Yogesh Agrawal Trust                                   |     | Promoter  | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 48.07                                  | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 65  | Ajanta Pharma Limited   |     | Rajesh M Agrawal, trustee Rajesh Agrawal Trust                                   |     | Promoter  | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 48.07                                  | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 66  | Ajanta Pharma Limited   |     | Ravi P Agrawal, trustee Ravi Agrawal Trust                                       |     | Promoter  | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 43.28                                  | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 67  | Ajanta Pharma Limited   |     | Aayush M Agrawal, trustee Aayush Agrawal Trust                                   |     | Promoter  | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 39.34                                  | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 68  | Ajanta Pharma Limited   |     | Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal |     | Promoter  | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 10.04                                  | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 69  | Ajanta Pharma Limited   |     | Arvind Agrawal   |     | Chief Financial Officer & KMP   | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 0.11                                   | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 70  | Ajanta Pharma Limited   |     | Gaurang Shah   |     | Company Secretary & KMP   | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 0                                      | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| 71  | Ajanta Pharma Limited   |     | Chandrakant Khetan   |     | Independent Director  | Any other transaction             | Buyback of Equity Shares                   | N.A.  | 0                                      | 0  | 0   |                 |   |                               |      |        |   |       |                   |
| <b>Total value of transaction during the reporting period</b> |   |     |  |     |   |                                   |  |   | <b>810.75</b>                          |  |   |                 |   |                               |      |        |   |       |                   |

Notes:

1) Amount approved by Audit Committee is for the entire financial year.

2) As per Regulation 23(5) of the SEBI (LODR) Regulation 2015, transactions entered into between a holding company and its wholly owned subsidiary whose accounts are consolidated with such holding company and placed before the shareholders at the general meeting for approval do not require prior approval of Audit Committee. Hence for transactions with all the wholly owned subsidiaries like dividend received, investments, trade and other receivables etc. at Sr. No. 5 to 9, 11, 12, 15 to 17, 49 and 50 (save and except for sale /purchase of goods), audit committee approval is not sought.

3) Transactions at Sr. No. 3, 18 to 32, 34 to 41, 43 to 48 and 53 to 71 pertaining to payment of dividend to promoters, contribution to gratuity trust, remuneration of Directors, their relatives &amp; KMPs, Director's sitting fees, buyback of shares etc. are at actuals and approval of Board was taken for the same.